Brief: Galmed Announces Initiation Of A Clinical Development Program To Evaluate Aramchol Meglumine For The Treatment Of Primary Sclerosing Cholangitis (Psc)

Eocene

09/05/2023 13:28

May 9 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED ANNOUNCES INITIATION OF A CLINICAL DEVELOPMENT
PROGRAM TO
EVALUATE ARAMCHOL MEGLUMINE FOR THE TREATMENT OF PRIMARY
SCLEROSING CHOLANGITIS (PSC)
    * GALMED PHARMACEUTICALS LTD - PLANS TO INITIATE A PHASE 2
STUDY
IN LAST QUARTER OF 2023

Source text for Eikon:  ID:nPn5JLnC2a 
Further company coverage:  GLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))